Viracta Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Viracta Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Viracta Therapeutics Inc Strategy Report
- Understand Viracta Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Viracta Therapeutics Inc (Viracta Therapeutics), develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company's pipeline products include Nana-val for the treatment of Lymphoma and Solid Tumors; SSN-510 for the treatment of hematology and solid tumors. The company had partnered programs under development include TAK-580 (formerly MLN2480) and Vosaroxin for the treatment of various types of cancer. The company entered into partnership with Biogen, Takeda, DOT Therapeutics-1, Inc, Denovo Biopharma, LLC for the development of pipeline products. Viracta is headquartered in Cardiff, California, the US.
Headquarters
United States of America
Address
2533 S Coast Hwy 101, Suite 210, Cardiff By The Sea, California, 92007
Website
www.viracta.com
Telephone
1 858 4008470
No of Employees
41
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VIRX (NASD)
EPS
XYZ
Net Income (2022)
XYZ
57.1%
(2022 vs 2021)
Market Cap*
$19.1M
Net Profit Margin (2020)
XYZ
-1,500.1%
(2022 vs 2021)
* As of and is in US$
Viracta Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline products: |
| Nana-val |
| SSN-510 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In January, the company announced that the European Commission (EC) has granted an orphan drug designation (ODD) to its all-oral combination product candidate, Nana-val for the treatment of diffuse large B-cell lymphoma (DLBCL). |
| 2022 | Regulatory Approval | In September, the company announced that Orphan Drug Designation has been granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma. |
| 2021 | Divestiture | In March, the company sold the potential future milestones and royalties associated with existing licenses relating to two clinical-stage drug candidates to XOMA Corp. |
Competitor Comparison
| Key Parameters | Viracta Therapeutics Inc | Gilead Sciences Inc | TG Therapeutics Inc | Infinity Pharmaceuticals Inc | Aptose Biosciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Canada |
| City | Cardiff By The Sea | Foster City | Morrisville | Cambridge | North York |
| State/Province | California | California | North Carolina | Massachusetts | Ontario |
| No. of Employees | 41 | 17,000 | 244 | 30 | 35 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Roger J. Pomerantz | Chairman | Executive Board | 2020 | 66 |
| Mark Rothera | Director; President; Chief Executive Officer | Executive Board | 2022 | - |
| Dan Chevallard | Chief Operating Officer; Chief Financial Officer | Senior Management | 2021 | - |
| Darrel P. Cohen, M.D | Chief Medical Officer | Senior Management | 2023 | - |
| Ayman El-Guindy, Ph.D. | Chief Scientific Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward